Curis (CRIS)
(Delayed Data from NSDQ)
$6.25 USD
0.00 (0.00%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $6.46 +0.21 (3.36%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRIS 6.25 0.00(0.00%)
Will CRIS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRIS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRIS
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?
CRIS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
Other News for CRIS
12 Health Care Stocks Moving In Monday's Intraday Session
Buy Rating Affirmed on Curis’s Emavusertib for Its Potential to Overcome Drug Resistance in AML and MDS
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed for Curis’s Emavusertib Following Promising Leukemia Study Results
Curis Announces Additional Data from TakeAim Leukemia Study